Jushi Holdings (JUSHF) Change in Accured Expenses (2021 - 2026)
Jushi Holdings (JUSHF) posted quarterly Change in Accured Expenses of -$3.2 million for Q2 2026, up 62.61% year-over-year from -$2.0 million in Q2 2025, and down 186.9% quarter-over-quarter from $3.7 million in Q1 2026.
Jushi Holdings (JUSHF) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has reported Change in Accured Expenses for 6 consecutive years, with -$3.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Accured Expenses rose 62.61% year-over-year to -$3.2 million; the TTM figure through Jun 2026 stood at $4.1 million (up 156.6% YoY), while the FY2025 annual figure was $893000.0, down 90.93% from the prior year.
- Change in Accured Expenses eased to -$3.2 million in Q2 2026 per JUSHF's latest filing, from $3.7 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $10.8 million in Q4 2022 and bottomed at -$10.6 million in Q3 2023.
- Historically, Change in Accured Expenses has averaged $1.7 million across 5 years, with a median of $2.1 million in 2024.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 437.66% — and 2025, when it plunged 1238.68%.
- Jushi Holdings' Change in Accured Expenses stood at $10.8 million in 2022, then tumbled by 117.74% to -$1.9 million in 2023, then jumped by 128.88% to $553000.0 in 2024, then slumped by 393.85% to -$1.6 million in 2025, then plunged by 95.88% to -$3.2 million in 2026.
- Business Quant data shows JUSHF's Change in Accured Expenses at -$3.2 million in Q2 2026, $3.7 million in Q1 2026, and -$1.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn | -3.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.18 Mn |
| Jun 30, 2026 | -3.18 Mn |
| Mar 31, 2026 | 3.66 Mn |
| Mar 31, 2026 | 3.66 Mn |
| Dec 31, 2025 | -1.63 Mn |
| Dec 31, 2025 | -1.63 Mn |
| Sep 30, 2025 | 5.28 Mn |
| Sep 30, 2025 | 5.28 Mn |
| Jun 30, 2025 | -8.51 Mn |
| Jun 30, 2025 | -8.51 Mn |
| Mar 31, 2025 | 5.75 Mn |
| Mar 31, 2025 | 5.75 Mn |
| Dec 31, 2024 | 553,000.00 |
| Dec 31, 2024 | 553,000.00 |
| Sep 30, 2024 | 3.83 Mn |
| Sep 30, 2024 | 3.83 Mn |
| Jun 30, 2024 | -636,000.00 |
| Jun 30, 2024 | -636,000.00 |
| Mar 31, 2024 | 6.10 Mn |
| Mar 31, 2024 | 6.10 Mn |